Folke Johnsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Folke Johnsson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
A.-C. Klintenberg
Dept. of Surgery, Lund University Hospital, Lund, Sweden; Dept. of Gastroenterology, Haukeland Hospital, University of Bergen, Bergen, Norway; AstraZeneca Sverige AB, Mölndal, Sweden; University Hospital MAS, Malmö, Sweden; Värnamo Hospital, Värnamo, Sweden; and Sahlgrenska University Hospital, Gothenburg, Sweden; Varberg Hospital, Varberg, Sweden
2 shared publicationsJ. G. Hatlebakk
Dept. of Surgery, Lund University Hospital, Lund, Sweden; Dept. of Gastroenterology, Haukeland Hospital, University of Bergen, Bergen, Norway; AstraZeneca Sverige AB, Mölndal, Sweden; University Hospital MAS, Malmö, Sweden; Värnamo Hospital, Värnamo, Sweden; and Sahlgrenska University Hospital, Gothenburg, Sweden; Varberg Hospital, Varberg, Sweden
2 shared publicationsJ. Román
Dept. of Surgery, Lund University Hospital, Lund, Sweden; Dept. of Gastroenterology, Haukeland Hospital, University of Bergen, Bergen, Norway; AstraZeneca Sverige AB, Mölndal, Sweden; University Hospital MAS, Malmö, Sweden; Värnamo Hospital, Värnamo, Sweden; and Sahlgrenska University Hospital, Gothenburg, Sweden; Varberg Hospital, Varberg, Sweden
2 shared publicationsA. Falk
Dept. of Surgery, Lund University Hospital, Lund, Sweden; Dept. of Gastroenterology, Haukeland Hospital, University of Bergen, Bergen, Norway; AstraZeneca Sverige AB, Mölndal, Sweden; University Hospital MAS, Malmö, Sweden; Värnamo Hospital, Värnamo, Sweden; and Sahlgrenska University Hospital, Gothenburg, Sweden; Varberg Hospital, Varberg, Sweden
1 shared publicationA. Stubberöd
Dept. of Surgery, Lund University Hospital, Lund, Sweden; Dept. of Gastroenterology, Haukeland Hospital, University of Bergen, Bergen, Norway; AstraZeneca Sverige AB, Mölndal, Sweden; University Hospital MAS, Malmö, Sweden; Värnamo Hospital, Värnamo, Sweden; and Sahlgrenska University Hospital, Gothenburg, Sweden; Varberg Hospital, Varberg, Sweden
1 shared publicationB Walther
1 shared publication
Latest Publications
- 9 April 2009
- Vol. 106 (8) , 499
[Surgical or medical treatment of gastroesophageal reflux? Surgery only when the drug treatment is not effective].
- 9 April 2009
- Vol. 106 (8) , 499
[Surgical or medical treatment of gastroesophageal reflux? Surgery only when the drug treatment is not effective].
- Open Access
- 30 April 2008
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 31
The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials
Background: Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods: Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results: The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion: The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.
- 30 April 2008
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 6 (1) , 31
Open AccessThe Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials
Background: Critical needs for treatment trials in gastroesophageal reflux disease (GERD) include assessing response to treatment, evaluating symptom severity, and translation of symptom questionnaires into multiple languages. We evaluated the previously validated Reflux Disease Questionnaire (RDQ) for internal consistency, reliability, responsiveness to change during treatment and the concordance between RDQ and specialty physician assessment of symptom severity, after translation into Swedish and Norwegian. Methods: Performance of the RDQ after translation into Swedish and Norwegian was evaluated in 439 patients with presumed GERD in a randomized, double-blind trial of active treatment with a proton pump inhibitor. Results: The responsiveness was excellent across three RDQ indicators. Mean change scores in patients on active treatment were large, also reflected in effect sizes that ranged from a low of 1.05 (dyspepsia) to a high of 2.05 (heartburn) and standardized response means 0.99 (dyspepsia) and 1.52 (heartburn). A good positive correlation between physician severity ratings and RDQ scale scores was seen. The internal consistency reliability using alpha coefficients of the scales, regardless of language, ranged from 0.67 to 0.89. Conclusion: The results provide strong evidence that the RDQ is amenable to translation and represents a viable instrument for assessing response to treatment, and symptom severity.
- 1 January 2003
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 38 (4) , 354-359
One-week Esomeprazole Treatment: an Effective Confirmatory Test in Patients with Suspected Gastroesophageal Reflux Disease
Background: Symptomatic response to acid inhibition can be used as a guide in diagnosing patients with reflux symptoms. The proton-pump inhibitor (PPI) omeprazole has been used as such a diagnostic tool. Intragastric acid control with esomeprazole is more effective than other PPIs and has the potential to offer an advance in the diagnostic use of PPIs. Methods: Patients experiencing heartburn (for ≥6 months) were studied in this randomized, double-blind, multicenter study. Following a 3-day placebo run-in, 440 patients were randomized to 14 days' treatment with esomeprazole 40 mg once daily (o.d.), esomeprazole 20 mg twice daily (b.i.d.) or placebo. Heartburn symptoms were recorded daily. Endoscopy and 24-h esophageal pH-monitoring were performed to determine the presence of gastroesophageal reflux disease (GERD). The esomeprazole treatment test was considered positive if patients' symptoms improved during the treatment period compared with symptoms recorded on Day 0. Results: 63 patients were excluded from the analysis due to lack of symptoms on Day 0 or failure to complete pH-monitoring. The sensitivity of an esomeprazole treatment test in confirming GERD increased during the first days of treatment and stabilized between 79% and 86% after 5 days (both esomeprazole arms). The corresponding figure for the placebo arm was 36%. Specificity was variable (24%-65%) for both active treatment and placebo. Conclusion: A treatment test with esomeprazole 40 mg has a high sensitivity in confirming GERD. Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis.
- 1 January 2003
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 38 (4) , 354-359
One-week Esomeprazole Treatment: an Effective Confirmatory Test in Patients with Suspected Gastroesophageal Reflux Disease
Background: Symptomatic response to acid inhibition can be used as a guide in diagnosing patients with reflux symptoms. The proton-pump inhibitor (PPI) omeprazole has been used as such a diagnostic tool. Intragastric acid control with esomeprazole is more effective than other PPIs and has the potential to offer an advance in the diagnostic use of PPIs. Methods: Patients experiencing heartburn (for ≥6 months) were studied in this randomized, double-blind, multicenter study. Following a 3-day placebo run-in, 440 patients were randomized to 14 days' treatment with esomeprazole 40 mg once daily (o.d.), esomeprazole 20 mg twice daily (b.i.d.) or placebo. Heartburn symptoms were recorded daily. Endoscopy and 24-h esophageal pH-monitoring were performed to determine the presence of gastroesophageal reflux disease (GERD). The esomeprazole treatment test was considered positive if patients' symptoms improved during the treatment period compared with symptoms recorded on Day 0. Results: 63 patients were excluded from the analysis due to lack of symptoms on Day 0 or failure to complete pH-monitoring. The sensitivity of an esomeprazole treatment test in confirming GERD increased during the first days of treatment and stabilized between 79% and 86% after 5 days (both esomeprazole arms). The corresponding figure for the placebo arm was 36%. Specificity was variable (24%-65%) for both active treatment and placebo. Conclusion: A treatment test with esomeprazole 40 mg has a high sensitivity in confirming GERD. Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis.
- 1 January 2003
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 38 (4) , 347-353
Symptom-relieving Effect of Esomeprazole 40 mg Daily in Patients with Heartburn
Background: To assess symptom relief in patients with heartburn following treatment with esomeprazole 40 mg daily. Methods: Patients with heartburn (for ≥6 months) were assessed in this double-blind, multicenter study. After a 3-day single-blind placebo run-in, 440 patients were randomized to esomeprazole 40 mg o.d., esomeprazole 20 mg b.i.d. or placebo for 14 days. Heartburn symptoms were recorded daily; as insufficient patients had data available from days 13 and 14, analyses included data up to day 12. Gastroesophageal reflux disease (GERD) was diagnosed by upper GI endoscopy and 24-h pH- monitoring. The primary end-point was total heartburn relief defined as no heartburn symptoms during the preceding 24-h period. Results: 240 patients had erosive esophagitis (EO) and 114 patients had GERD defined by pH-monitoring. Proportions of patients with total heartburn relief increased during the first days of treatment and stabilized after Day 4. Total heartburn relief occurred in 67%-73%, 62%-70%, and 21%-32% of patients in the esomeprazole 40 mg o.d., esomeprazole 20 mg b.i.d., and placebo groups, respectively, between days 6 and 12. Proportions of patients with total heartburn relief were higher in patients with EO (71%-80% of patients from Day 4 onwards) compared to those without EO (52%-67% of patients from Day 4 onwards). Figures for patients diagnosed by pH-monitoring were 65%-73% of those with a positive diagnosis and 51%-58% with a negative diagnosis. Conclusion: Esomeprazole 40 mg o.d. treatment produces total heartburn relief in a high proportion of patients with GERD. Once-daily esomeprazole 40 mg dosing is recommended as no advantage was gained by splitting the dose.
- 1 January 2003
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 38 (4) , 347-353
Symptom-relieving Effect of Esomeprazole 40 mg Daily in Patients with Heartburn
Background: To assess symptom relief in patients with heartburn following treatment with esomeprazole 40 mg daily. Methods: Patients with heartburn (for ≥6 months) were assessed in this double-blind, multicenter study. After a 3-day single-blind placebo run-in, 440 patients were randomized to esomeprazole 40 mg o.d., esomeprazole 20 mg b.i.d. or placebo for 14 days. Heartburn symptoms were recorded daily; as insufficient patients had data available from days 13 and 14, analyses included data up to day 12. Gastroesophageal reflux disease (GERD) was diagnosed by upper GI endoscopy and 24-h pH- monitoring. The primary end-point was total heartburn relief defined as no heartburn symptoms during the preceding 24-h period. Results: 240 patients had erosive esophagitis (EO) and 114 patients had GERD defined by pH-monitoring. Proportions of patients with total heartburn relief increased during the first days of treatment and stabilized after Day 4. Total heartburn relief occurred in 67%-73%, 62%-70%, and 21%-32% of patients in the esomeprazole 40 mg o.d., esomeprazole 20 mg b.i.d., and placebo groups, respectively, between days 6 and 12. Proportions of patients with total heartburn relief were higher in patients with EO (71%-80% of patients from Day 4 onwards) compared to those without EO (52%-67% of patients from Day 4 onwards). Figures for patients diagnosed by pH-monitoring were 65%-73% of those with a positive diagnosis and 51%-58% with a negative diagnosis. Conclusion: Esomeprazole 40 mg o.d. treatment produces total heartburn relief in a high proportion of patients with GERD. Once-daily esomeprazole 40 mg dosing is recommended as no advantage was gained by splitting the dose.
- 1 June 1997
- Vol. 163 (6) , 469-71
Development of adenocarcinoma in Barrett's oesophagus after successful antireflux surgery.
- 1 June 1997
- Vol. 163 (6) , 469-71
Development of adenocarcinoma in Barrett's oesophagus after successful antireflux surgery.